Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
In: Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 9647-9649
academicJournal
Zugriff:
Titel: |
Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
|
---|---|
Autor/in / Beteiligte Person: | Cortes, Jorge E. ; Jiang, Qian ; Wang, Jianxiang ; Weng, Jianyu ; Zhu, Huanling ; Liu, Xiaoli ; Hochhaus, Andreas ; Kim, Dong-Wook ; Radich, Jerald ; Savona, Michael R. ; Martin-Regueira, Patricia ; Sy, Oumar ; Saglio, Giuseppe |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 9647-9649 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0006-4971 (electronic) |
DOI: | 10.1182/blood-2022-164444 |
Sonstiges: |
|